Erica Novo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8419492/publications.pdf

Version: 2024-02-01

126907 4,241 55 33 citations h-index papers

g-index 56 56 56 6262 citing authors docs citations times ranked all docs

168389

53

#	Article	IF	Citations
1	Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis and Tissue Repair, 2008, 1, 5.	3.4	328
2	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology, 2005, 42, 1339-1348.	7.3	310
3	Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer cells. Carcinogenesis, 2008, 29, 2267-2278.	2.8	274
4	Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut, 2008, 57, 223-231.	12.1	248
5	Epithelial–Mesenchymal Transition: From Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease. Antioxidants and Redox Signaling, 2010, 12, 1383-1430.	5.4	226
6	The upâ€regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1α. Journal of Neurochemistry, 2009, 108, 1045-1056.	3.9	217
7	Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells. American Journal of Pathology, 2007, 170, 1942-1953.	3.8	196
8	Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. Journal of Hepatology, 2009, 50, 1102-1111.	3.7	186
9	Cellular and molecular mechanisms in liver fibrogenesis. Archives of Biochemistry and Biophysics, 2014, 548, 20-37.	3.0	177
10	Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut, 2005, 55, 1174-1182.	12.1	143
11	Liver fibrosis: a dynamic and potentially reversible process. Histology and Histopathology, 2010, 25, 1075-91.	0.7	110
12	Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. Journal of Hepatology, 2011, 54, 964-974.	3.7	109
13	Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 477-488.	4.5	104
14	4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. Journal of Hepatology, 2004, 40, 60-68.	3.7	103
15	Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. Journal of Hepatology, 2007, 46, 230-238.	3.7	93
16	Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World Journal of Gastroenterology, 2010, 16, 281.	3.3	91
17	Hepatic myofibroblasts: A heterogeneous population of multifunctional cells in liver fibrogenesis. International Journal of Biochemistry and Cell Biology, 2009, 41, 2089-2093.	2.8	87
18	Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Laboratory Investigation, 2010, 90, 104-115.	3.7	84

#	Article	IF	CITATIONS
19	Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut, 2006, 55, 90-97.	12.1	78
20	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. International Journal of Molecular Medicine, 2010, 26, 471-6.	4.0	78
21	ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. International Journal of Molecular Sciences, 2019, 20, 2700.	4.1	72
22	The biphasic nature of hypoxiaâ€induced directional migration of activated human hepatic stellate cells. Journal of Pathology, 2012, 226, 588-597.	4.5	71
23	Hypoxiaâ€inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidineâ€rich glycoprotein. Hepatology, 2018, 67, 2196-2214.	7.3	66
24	Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clinical Science, 2012, 123, 459-471.	4.3	59
25	Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget, 2015, 6, 2206-2221.	1.8	59
26	Angiogenesis and liver fibrogenesis. Histology and Histopathology, 2009, 24, 1323-41.	0.7	55
27	Dissection of the Biphasic Nature of Hypoxia-Induced Motogenic Action in Bone Marrow-Derived Human Mesenchymal Stem Cells. Stem Cells, 2011, 29, 952-963.	3.2	51
28	Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Advanced Drug Delivery Reviews, 2017, 121, 57-84.	13.7	51
29	The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis and Tissue Repair, 2012, 5, S4.	3.4	50
30	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. PLoS ONE, 2017, 12, e0172575.	2.5	49
31	Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2011, 301, G210-G219.	3.4	39
32	NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling. Clinical Science, 2016, 130, 1793-1806.	4.3	39
33	Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases. Histology and Histopathology, 2014, 29, 33-44.	0.7	37
34	Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis. Cells, 2021, 10, 1764.	4.1	35
35	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. Cells, 2020, 9, 28.	4.1	26
36	SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells. Scientific Reports, 2017, 7, 3420.	3.3	23

#	Article	IF	CITATIONS
37	SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. Cancers, 2019, 11, 1933.	3.7	22
38	Nrf1 gene expression in the liver: A single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. Journal of Hepatology, 2005, 43, 1096-1097.	3.7	21
39	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. American Journal of Physiology - Renal Physiology, 2006, 290, G120-G128.	3.4	19
40	Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases. Histology and Histopathology, 2015, 30, 1011-32.	0.7	18
41	ß-Catenin triggers nuclear factor ?B-dependent up-regulation of hepatocyte inducible nitric oxide synthase. International Journal of Biochemistry and Cell Biology, 2008, 40, 1861-1871.	2.8	17
42	nâ€3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. Liver International, 2014, 34, 918-930.	3.9	17
43	Liver fibrogenesis: un update on established and emerging basic concepts. Archives of Biochemistry and Biophysics, 2020, 689, 108445.	3.0	15
44	Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data. PLoS ONE, 2016, 11, e0162644.	2.5	14
45	Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 459-482.	4.5	13
46	Oncostatin <scp>M</scp> is overexpressed in <scp>NASH</scp> â€related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Journal of Pathology, 2022, 257, 82-95.	4.5	12
47	4â€Hydroxyâ€2,3â€alkenals as signal molecules modulating proliferative and adaptative cell responses. BioFactors, 2001, 15, 103-106.	5.4	10
48	SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, $0,13,1$	4.8	9
49	HDL cholesterol protects from liver injury in mice with intestinal specific LXRÎ \pm activation. Liver International, 2020, 40, 3127-3139.	3.9	8
50	Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis. Antioxidants, 2022, 11, 1278.	5.1	8
51	Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block. Hepatology International, 2013, 7, 299-305.	4.2	4
52	Hepatic Angiogenesis and Fibrogenesis in the Progression of Chronic Liver Diseases. Current Angiogenesis, 2013, 2, 23-29.	0.1	3
53	Oxidative Stress and Liver Fibrogenesis. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 171-196.	0.4	2
54	In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future?. Stem Cell Investigation, 2016, 3, 53-53.	3.0	1

#	Article	IF	CITATIONS
55	Hyperdynamic circulatory syndrome in a mouse model transgenic for SerpinB3. Annals of Hepatology, 2020, 19, 36-43.	1.5	1